aha 2021: empatropism fe: effects of empagliflozin on iron metabolism in non-diabetic hf patients
Published 2 years ago • 357 plays • Length 2:17Download video MP4
Download video MP3
Similar videos
-
2:38
aha 2021: emperor-preserved: empagliflozin, health status, & qol in patients with hfpef | dr butler
-
2:30
aha 2021: what has iron to do with hf and cardiac function | prof christiane e angermann
-
3:57
aha 2019: empagliflozin on erythropoietin levels – dr david mazer
-
5:01
aha 22: emperor-pooled: clinical outcomes & efficacy of empagliflozin in black vs white pts with hf
-
5:09
aha 2021 late-breaker discussion: the empulse trial
-
5:14
risk for heart failure modulate the effectiveness of empagliflozin ?
-
6:01
aha 2021 late-breaker discussion: the chief-hf clinical trial
-
6:57
hfa 2020: dapagliflozin and diuretic use in patients with hfref in dapa-hf — dr alice m jackson
-
7:24
empulse trial. empagliflozin in acute heart failure. aha2021
-
3:35
hf 2022: deliver extends benefits of dapagliflozin to the full spectrum of pts with hf
-
6:28
emperor-reduced: empagliflozin benefits in hf patients irrespective of diabetes | milton packer
-
13:30
aha 22: late-breaker discussion: the transform-hf trial
-
20:09
esc 2021 discussion: the emperor-pooled study | dr harriette van spall & dr milton packer
-
4:45
esc 2022: the emperor-pooled trial: clinical benefits of sglt2i in heart failure | dr faiez zannad
-
0:45
american heart association (aha) 2021 at radcliffe cardiology | teaser
-
7:10
empulse results
-
4:49
aha 2016 | precision
-
11:39
ehj today - confirm trial